Researcher
Peter Van Dam
- Research Expertise:Translational investigations in breat and cervical cancer Immune environment in inflammatory breast cancer and cervical cancer Effect of Denosumab on the immune environment of cervical cancer Quality control of cancer treatment Telemonitoring of sidde effects of cancer treatment Cognitive impairment after cancer treatment
- Keywords:T CYTOTOXIC LYMPHOCYTE, T HELPER LYMPHOCYTE, Medicine
- Disciplines:Cancer biology, Cancer diagnosis, Cancer therapy
- Research techniques:Immunohistochemical staining Flow cytometry RNA seq
- Users of research expertise:Other interested groups
Affiliations
- Center for Oncological Research (CORE) (Research group)
Member
From1 Jan 2019 → Today - Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO) (Research group)
Member
From1 Feb 2014 → 31 Dec 2018
Projects
1 - 10 of 10
- Establishing patient-derived organoids to rationally design therapies for patients with inflammatory breast cancerFrom1 Nov 2023 → TodayFunding: Nonprofit institution or equivalents
- Reinvigorating the antitumor immunity in human breastand cervical cancer with an innovative RANK(L) targeted combination strategy.From1 Nov 2021 → TodayFunding: Nonprofit institution or equivalents
- Development and validation of a novel rationally designed immunotherapeutic combination strategy built upon targeting RANK(L) for cervical cancer.From1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Acquired immunity and immunologic aspects of SARS-CoV-2 infection a population of patients and healthcare workers in Multidisciplinary Oncologic Centres. (MOCOR-Study).From1 Jun 2020 → 31 May 2021Funding: BOF - projects
- Unveiling the drug repurposing versatility of denosumab in the battle against human cervical cancer.From1 Jan 2020 → 31 Dec 2020Funding: Nonprofit institution or equivalents
- Integrated Personalized & Precision Oncology Network (IPPON).From1 Jan 2020 → TodayFunding: BOF - research organisations, Fund Recuperation Fiscal Exemption
- The role of infiltrating immune cells in the aggresive phenotype of inflammatory breast cancer and possible new (immuno)therapeutic targets.From1 Oct 2018 → 30 Sep 2020Funding: FWO fellowships
- RANK signaling and checkpoint inhibition.From15 Sep 2018 → 14 Sep 2021Funding: Nonprofit institution or equivalents
- The role of infiltrating immune cells in the aggresive phenotype of inflammatory breast cancer and possible new (immuno)therapeutic targets.From1 Oct 2016 → 30 Sep 2018Funding: FWO fellowships
- Characterization of the stromal component in inflammatory breast cancer.From15 Jan 2016 → 14 Jan 2017Funding: Nonprofit institution or equivalents
Publications
21 - 30 of 108
- Improved characteristics of RANKL immuno-PET imaging using radiolabeled antibody fab fragments(2022)
Authors: Ivanna Hrynchak, Sarah Geudens, Isabel Pintelon, Christel Vangestel, José Sereno, Peter Van Dam, Antero J. Abrunhosa, Filipe Elvas, Tim Van den Wyngaert
Pages: 1 - 16 - Targeting hedgehog signaling in pancreatic ductal adenocarcinoma(2022)
Authors: Delphine Quatannens, Yannick Verhoeven, Peter Van Dam, Filip Lardon, Hans Prenen, Geert Roeyen, Marc Peeters, Evelien Smits, Jonas Van Audenaerde
- The tele-transition of toxicity management in routine oncology care during the severe acute respiratory syndrome (SARS-CoV-2) pandemic(2021)
Authors: Marika Rasschaert, Pieterjan Vanclooster, Tim Mertens, Ella Roelant, Katrien Lesage, Hans Prenen, Ilse van Brussel, Jo Ravelingien, Peter Van Dam, Marc Peeters
Pages: 1366 - 1372 - Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors(2021)
Authors: Francois Bertucci, Laurys Boudin, Pascal Finetti, Christophe Van Berckelaer, Peter Van Dam, Luc Dirix, Patrice Viens, Anthony Goncalves, Naoto T. Ueno, Steven Van Laere, et al.
- Cancer-associated fibroblasts as a common orchestrator of therapy resistance in lung and pancreatic cancer(2021)
Authors: Delphine Quatannens, Sara Zanivan, Christophe Deben, Jonas Van Audenaerde, Evelien Smits, An Wouters, Filip Lardon, Geert Roeyen, Yannick Verhoeven, Timon Vandamme, et al.
- Targeting the PD-1 axis with pembrolizumab for recurrent or metastatic cancer of the uterine cervix(2021)
Authors: Yannick Verhoeven, Delphine Quatannens, Xuan Bich Trinh, An Wouters, Evelien Smits, Filip Lardon, Jorrit De Waele, Peter Van Dam
- The evolution and prognostic role of tumour-infiltrating lymphocytes and peripheral blood-based biomarkers in inflammatory breast cancer patients treated with neoadjuvant chemotherapy(2021)
Authors: Christophe Van Berckelaer, Iris Vermeiren, Leonie Vercauteren, Charlotte Rypens, Gizem Öner, Xuan Bich Trinh, Wiebren Tjalma, Emmanuelle Charafe-Jauffret, Steven Van Laere, Francois Bertucci, et al.
- Anthracyclines strike back(2021)
Authors: Francesco Schettini, Mario Giuliano, Matteo Lambertini, Rupert Bartsch, David James Pinato, Concetta Elisa Onesti, Nadia Harbeck, Diana Lueftner, Sylvie Rottey, Peter Van Dam, et al.
- Immuno-PET molecular imaging of RANKL in cancer(2021)
Authors: Christel Vangestel, Yannick Verhoeven, Jorrit De Waele, Karen Zwaenepoel, Peter Van Dam, Filipe Elvas, Tim Van den Wyngaert
- Blood cytokine analysis suggests that SARS-CoV-2 infection results in a sustained tumour promoting environment in cancer patients(2021)
Authors: Fien De Winter, An Hotterbeekx, Manon Huizing, Angelina Konnova, Erik Fransen, Bart 's Jongers, Ravi Kumar Jairam, Vincent Van Averbeke, Pieter Moons, Ella Roelant, et al.
Pages: 1 - 19